Akums Drugs & Pharma

572.30
+2.95
(0.52%)
Market Cap
9,007.66 Cr
EPS
-0.28
PE Ratio
27.55
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,175.90
52 Week Low
405.00
PB Ratio
2.94
Debt to Equity
0.83
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,687.80
#1 4,04,959.76
35.29
#1 49,887.20
12.06
#1 9,648
-18.99
46.16
6,667.00
1,76,987.90
81.46
8,184.00
0.89
1,600
23.05
60.61
1,505.20
1,21,562.20
23.01
26,520.70
14.17
4,155
30.28
53.87
1,362.50
1,13,694.54
20.11
28,905.40
12.36
5,578
21.14
84.56
3,252.50
1,10,079.38
57.23
10,785.70
11.59
1,656
10.91
56.97
2,381.30
98,247.32
49.58
10,615.60
19.57
1,942
-10.91
43.09
974.95
98,102.78
21.09
19,831.50
13.82
3,831
-0.19
71.52
1,999.60
91,289.93
28.14
20,141.50
#1 19.94
1,936
#1 112.49
49.72
31,515.00
66,967.18
47.29
6,097.20
10.80
1,201
27.83
59.42
1,150.20
66,803.80
#1 19.42
29,559.20
17.55
3,169
-0.50
44.60

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
12.48 %
Net Income Growth
-99.18 %
Cash Flow Change
182.09 %
ROE
-99.19 %
ROCE
-97.66 %
EBITDA Margin (Avg.)
-63.65 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
978
1,188
1,093
955
1,026
1,050
1,030
1,081
Expenses
1,095
1,057
989
941
891
912
889
962
EBITDA
-117
131
103
14
135
138
141
120
Operating Profit %
-13 %
11 %
9 %
0 %
13 %
12 %
12 %
9 %
Depreciation
30
30
32
34
34
35
45
40
Interest
12
14
12
12
13
12
5
5
Profit Before Tax
-159
87
59
-33
88
92
91
75
Tax
29
54
-136
7
26
25
25
-75
Net Profit
-187
33
195
-40
61
67
66
150
EPS in ₹
-13.16
2.22
13.21
-2.89
4.21
4.37
4.26
9.64

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
Total Assets
2,078
2,192
3,069
3,267
3,516
Fixed Assets
645
834
1,021
1,097
1,191
Current Assets
1,250
1,157
1,864
1,879
1,941
Capital Work in Progress
57
87
31
103
195
Investments
6
19
0
0
0
Other Assets
1,371
1,252
2,017
2,066
2,130
Total Liabilities
2,078
2,192
3,069
3,267
3,516
Current Liabilities
730
580
1,272
1,266
1,211
Non Current Liabilities
627
725
1,172
1,278
1,585
Total Equity
721
887
625
723
721
Reserve & Surplus
721
884
608
689
681
Share Capital
1
1
14
29
29

Cash Flow

Cash Flow
2015
2016
2020
2021
2022
2023
2024
Net Cash Flow
-11
4
71
-70
33
-4
59
Investing Activities
-150
-123
-190
-109
-235
-305
-331
Operating Activities
72
89
28
135
32
177
498
Financing Activities
66
37
233
-95
236
125
-108

Share Holding

% Holding
Feb 2024
Aug 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
84.91 %
75.26 %
75.26 %
75.26 %
75.26 %
FIIs
0.00 %
5.32 %
7.34 %
6.36 %
5.77 %
DIIs
0.00 %
7.60 %
7.52 %
7.00 %
7.40 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
4.43 %
2.11 %
3.33 %
3.41 %
Others
15.09 %
7.38 %
7.77 %
8.05 %
8.16 %
No of Share Holders
8
1,38,205
57,531
68,410
69,366

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %

No dividends have been distributed by the company in the past 10 years

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
18 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
18 Jul 2025 566.05 569.35
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 May 2025 546.50 566.05
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 566.55 570.30
09 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
09 Nov 2024 845.30 796.60

Announcements

Intimation Of Approval Of Revised Notice Of Annual General Meeting (AGM)6 days ago
Intimation Of Appointment Of Additional Director (Non-Executive- Independent)9 days ago
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 26, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 26, 2025
Appointment Of SPG & Associates As A Secretarial Auditor Appointment Of Balwinder & Associates As Cost Auditor And Resignation Of Mr. Amrut Medhekar CEO-CDMOMay 26, 2025
Board Meeting Outcome for Outcome Of Board MeetingMay 26, 2025
Outcome Of Board MeetingMay 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 22, 2025
Board Meeting Intimation for Consideration And Approval Of Un-Audited (Standalone & Consolidated) Financial Results For The Quarter Ended On 31St March 2025 And Audited (Standalone & Consolidated) Financial Statements For The Year Ended On 31St March 2025May 19, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 17, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 14, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 07, 2025
Closure of Trading WindowMar 29, 2025
Resignation Of Senior Management PersonnelMar 26, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 15, 2025
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Grant Of PatentFeb 14, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 11, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 11, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 07, 2025
Statement Of Deviation.Feb 07, 2025
Integrated Filing (Financial)Feb 07, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 07, 2025
Un-Audited Financial Results For The Quarter And Nine Months Ended December 31 2024.Feb 07, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 06Th February 2025Feb 06, 2025
Announcement under Regulation 30 (LODR)-CessationFeb 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 03, 2025
Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December 2024.Feb 01, 2025
Update On Income Tax SearchJan 23, 2025
Income Tax SearchJan 22, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 11, 2025
Change Of Name Of RTAJan 02, 2025
Closure of Trading WindowDec 28, 2024
Shareholder Meeting / Postal Ballot-Scrutinizers ReportDec 17, 2024
Submission Of Additional Details As Per SEBI Circular No. SEBI/HO/CFD/Cfdpod-1/P/CIR/2023/123 Dated 13Th July 2023 On Our Disclosure Dated 19Th November, 24 On Execution Of Exclusive Master Sales Agreement With Caregen Co., Ltd.Nov 26, 2024
Akums Exclusively Ties Up With Jagdale For Marketing Of Ready-To-Drink Nutritional Beverages In Aseptic Carton TechnologyNov 26, 2024
Execution Of Exclusive Master Sales Agreement With Caregen Co., Ltd ('Caregen')Nov 19, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 15, 2024

Technical Indicators

RSI(14)
Neutral
58.27
ATR(14)
Volatile
19.02
STOCH(9,6)
Neutral
43.29
STOCH RSI(14)
Neutral
34.20
MACD(12,26)
Bearish
-2.00
ADX(14)
Strong Trend
39.52
UO(9)
Bearish
40.49
ROC(12)
Downtrend And Accelerating
-1.39
WillR(14)
Neutral
-74.55

Mutual Fund Holdings

Funding HouseNo of SharesCurrent Holding %1M Change %3M Change %Month
Nippon India Pharma Fund Direct-Growth
833718
0.57%
0.37%
0.57%
May 2025
SBI Conservative Hybrid Fund Direct-Growth
0
0.00%
-0.20%
-0.23%
May 2025
Groww Value Fund Direct-Growth
20608
2.14%
2.14%
2.14%
May 2025
JM Small Cap Fund Direct - Growth
130114
1.03%
-0.17%
-0.12%
May 2025
SBI Healthcare Opportunities Fund Direct Plan-Growth
800000
1.24%
0.09%
0.15%
May 2025
JM Value Fund Direct Plan-Growth
179498
0.94%
0.02%
0.07%
May 2025
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
32676
0.08%
0.00%
0.00%
May 2025
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
16605
0.23%
0.00%
0.03%
May 2025
SBI Nifty Smallcap 250 Index Fund Direct - Growth
20494
0.08%
0.00%
0.00%
May 2025
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
13238
0.08%
0.00%
0.01%
May 2025
Axis Nifty 500 Index Fund Direct-Growth
414
0.01%
0.00%
0.00%
May 2025
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
6818
0.08%
0.00%
0.00%
May 2025
Motilal Oswal Nifty 500 Index Fund Direct - Growth
3416
0.01%
0.00%
0.00%
May 2025
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
1958
0.08%
0.00%
0.00%
May 2025
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
7172
0.08%
0.00%
0.01%
May 2025
Groww Nifty Smallcap 250 Index Fund Direct - Growth
1609
0.08%
0.00%
0.01%
May 2025
Kotak Nifty Smallcap 250 Index Fund Direct-Growth
358
0.08%
0.00%
0.00%
May 2025
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth
104
0.02%
0.00%
0.00%
May 2025
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
1708
0.02%
0.00%
0.00%
May 2025
SBI Nifty 500 Index Fund Direct-Growth
1255
0.01%
0.00%
0.00%
May 2025
ICICI Prudential Nifty 500 Index Fund Direct-Growth
36
0.01%
0.00%
0.00%
May 2025
Angel One Nifty Total Market Index Fund Direct - Growth
52
0.01%
0.00%
0.00%
May 2025
Mirae Asset Nifty Total Market Index Fund Direct-Growth
58
0.01%
0.00%
0.00%
May 2025
Bandhan BSE Healthcare Index Fund Direct-Growth
382
0.12%
0.01%
0.02%
May 2025
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
791
0.08%
0.00%
0.00%
May 2025

About Akums Drugs & Pharma

Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) established in 2004. The company offers a wide range of pharmaceutical products and services both domestically and internationally. Their operations include manufacturing of Active Pharmaceutical Ingredients (APIs), sale of branded pharmaceutical formulations, formulation research and development, regulatory dossier preparation and filing, and testing services. Akums has manufacturing units accredited by global regulatory agencies and specializes in various therapeutic areas. The company has expanded through acquisitions and establishment of new facilities over the years. It operates in three main segments: CDMO, API, and Branded and Generic formulations. Akums has manufactured over 4,000 commercialized formulations across more than 60 dosage forms.
Listing Date
06 Aug, 2024(0 Years, 39 days)